 Sanofi SA said Saturday that its multiple-sclerosis treatment Lemtrada has been approved for sale in the U.S., nearly a year after regulators rejected the drug because of concerns about its serious side effects and the way the drug was tested in clinical studies.. The drug will be marketed by Cambridge, Mass.-based Genzyme Corp., which Sanofi acquired in 2011 for $20 billion. Former Sanofi Chief Executive Christopher Viehbacher, who was fired last month amid tensions with the French pharmaceutical companyâ€™s board, had made...
  